Key terms

About SLDB

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest SLDB news

Apr 01 7:47am ET Solid Biosciences receives Rae Pediatric Disease designation for SGT-003 by TipRanks Mar 28 9:52am ET Palantir downgraded, CyberArk initiated: Wall Street’s top analyst calls by TipRanks Mar 28 7:03am ET Solid Biosciences initiated with an Outperform at William Blair by TipRanks Mar 19 1:38am ET Cautious Optimism Amidst Clinical Progress and Regulatory Hurdles for Solid Biosciences by TipRanks Mar 18 5:51am ET Solid Biosciences price target raised to $21 from $8 at Barclays by TipRanks Mar 18 3:05am ET Solid Biosciences (SLDB) Gets a Buy from Barclays by TipRanks Mar 14 8:41pm ET Solid Biosciences initiated with a Buy at Citi by TipRanks Mar 14 8:30pm ET Analysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Solid Biosciences (SLDB) by TipRanks Mar 14 6:26am ET Buy Rating Affirmed for Solid Biosciences on Promising Pipeline and Financial Stability by TipRanks Mar 13 4:10pm ET Piper upgrades Solid Biosciences to Overweight, still sees ‘significant upside’ by TipRanks Mar 13 4:07pm ET Solid Biosciences upgraded to Overweight from Neutral at Piper Sandler by TipRanks Mar 13 9:26am ET Solid Biosciences files $300M mixed securities shelf by TipRanks Mar 13 7:48am ET Solid Biosciences expects cash to fund strategic priorities into 2026 by TipRanks Mar 13 7:48am ET Solid Biosciences reports 2023 EPS ($4.83), consensus ($4.72) by TipRanks Mar 11 6:17am ET Solid Biosciences price target raised to $16 from $9 at H.C. Wainwright by TipRanks Mar 11 12:48am ET Leerink Partners Keeps Their Hold Rating on Solid Biosciences (SLDB) by TipRanks Mar 07 7:12am ET Solid Biosciences announces licensing agreement with Armatus Bio by TipRanks Feb 05 4:06am ET Hold Rating on Solid Biosciences Amid Gene Therapy Developments and Regulatory Milestones by TipRanks Jan 30 4:12pm ET Solid Biosciences files to sell 19.685M shares of common stock for holders by TipRanks Jan 22 1:12pm ET Piper Sandler Reaffirms Their Hold Rating on Solid Biosciences (SLDB) by TipRanks Jan 11 6:14pm ET Solid Biosciences’ treatment of DMD granted FDA orphan designation by TipRanks Jan 08 9:57am ET Solid Biosciences trading resumes by TipRanks Jan 08 9:47am ET Solid Biosciences trading halted, volatility trading pause by TipRanks Jan 08 8:04am ET Solid Biosciences to sell 16.97M shares at $5.53 in private placement by TipRanks

No recent press releases are available for SLDB

SLDB Financials

1-year income & revenue

Key terms

SLDB Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

SLDB Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming
Tim Wren, chief commercial officer for BSI Group, right, presents Kristalina Georgieva, chief executive officer of the World Bank Group, second right, with ISO 20121 certification for sustainable event management at an event during the spring meetings of the International Monetary Fund (IMF) and World Bank in Washington, DC, US, on Monday, April 15, 2024. The IMF and World Bank spring meetings in Washington are expected to draw thousands of delegates, observers and journalists from the fund's 190 member countries. Photographer: Samuel Corum/Bloomberg via Getty Images
Samuel Corum/Bloomberg/Getty Images
Geopolitical strife is roiling Wall Street. Here’s what investors are watching